Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

€7.4bn ‘Just The Start’ For Global COVID-19 Drug & Vaccine Funding Project

Challenges Huge, Calls For IP On Coronavirus Tools To Be Pooled

Executive Summary

It’s not enough just to develop new drugs and vaccines for COVID-19. These tools must be made available to all those who need them wherever they are; for this to happen, health systems will need to be strengthened, say the backers of an EU-led funding initiative. Industry says it has already brought considerable resources to the table and stresses that close international cooperation will be vital if the pandemic is to be tackled effectively.

You may also be interested in...



WHO Launches Global Push For Tools To Tackle COVID-19

A global collaboration initiative launched by the World Health Organization is intended to foster the development of COVID-19 vaccines, medicines and diagnostics and to make sure they reach all those who need them. 

EU Targets Generics, Inspection Shortfalls & Environmental Assessments

As the European Commission prepares to publish its proposals for overhauling the EU pharmaceutical legislation at the end of the year, member states have been discussing a range of technical and legal issues such as the scope of the centralized approval procedure, the use of electronic product information and the shortage of inspection capacities.

EMA Reviewing Bavarian Nordic’s Imvanex For Vaccination Against Monkeypox

EU member state authorities have been told they can use Jynneos, the US version of Bavarian Nordic’s smallpox vaccine, for the prevention of monkeypox. The bloc is also buying some 110,000 doses of the vaccine, with deliveries expected to begin shortly.

Topics

Latest News
UsernamePublicRestriction

Register

PS142138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel